Vaccination against tumor neovascularization: Promise and reality.
Immunization against angiogenic-associated antigens selectively expressed on tumor vasculature provides for a novel strategy to block tumor growth. The feasibility of this approach has recently been borne out in several reports demonstrating that the protein or DNA of angiogenic molecules, such as VEGF-R2, can be used as vaccines to generate an effective cytotoxic T cell and antibody response against tumor vessels, thereby blocking tumor growth and metastasis.
Rafii
Shahin
S
Cornell University Medical College, Division of Hematology-Oncology, 1300 York Avenue, Room D601, New York, NY 10021, USA. srafii@med.cornell.edu
D000818:Animals; D019496:Cancer Vaccines / Q000009:adverse effects; D004730:Endothelium, Vascular / Q000276:immunology; D005818:Genetic Engineering; D006801:Humans; D007108:Immune Tolerance; D009369:Neoplasms / Q000098:blood supply* / Q000276:immunology* / Q000628:therapy; D009389:Neovascularization, Pathologic / Q000276:immunology* / Q000517:prevention & control; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000276:immunology*
D019496:Cancer Vaccines; D040301:Vascular Endothelial Growth Factor Receptor-2